Recombinant fusion proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M inhibit the proliferation of breast cancer cells in vitro

  • Authors:
    • Jikai Yin
    • Lijuan Yuan
    • Ziyu Liu
    • Fanglin Zhang
    • Xianli He
    • Zhikai Xu
    • Qing Wang
    • Xilin Du
    • Xing'an Wu
    • Jianguo Lu
  • View Affiliations

  • Published online on: April 7, 2014     https://doi.org/10.3892/or.2014.3130
  • Pages: 2669-2675
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Growth factor receptor bound protein 2 (Grb2) is a key adaptor performing a principal role in the oncogenic Ras signaling pathway. In the present study, we generated two fusion proteins. One contained an Src homology 2 (SH2) domain of Grb2, a signal peptide sequence, FLAG-tag sequence, PTD region and we named it FPTD-Grb2-SH2, while the other contained one mutant SH2 domain, added to a signal peptide sequence, FLAG-tag sequence, PTD region and we named it FPTD-Grb2-SH2M. Western blot analysis and immunofluorescence assay were used to investigate the expression and location of the fusion proteins in breast cancer cells. The proliferation and migration of the cells were estimated by MTT and Transwell cell migration assays, respectively. Flow cytometric analysis was performed to evaluate the apoptosis of the breast cancer cells. The recombinant proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M were successfully expressed in the breast cancer cell lines regardless of HER2-phenotype, and they suppressed breast cancer cell growth and migration as expected from the lack of SH3 domain. Both FPTD-Grb2-SH2 and FPTD-Grb2-SH2M exhibited significant toxicity to breast cancer cells. The present study demonstrated that the recombinant proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M may be used for anticancer drug development.
View Figures
View References

Related Articles

Journal Cover

June-2014
Volume 31 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yin J, Yuan L, Liu Z, Zhang F, He X, Xu Z, Wang Q, Du X, Wu X, Lu J, Lu J, et al: Recombinant fusion proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M inhibit the proliferation of breast cancer cells in vitro. Oncol Rep 31: 2669-2675, 2014.
APA
Yin, J., Yuan, L., Liu, Z., Zhang, F., He, X., Xu, Z. ... Lu, J. (2014). Recombinant fusion proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M inhibit the proliferation of breast cancer cells in vitro. Oncology Reports, 31, 2669-2675. https://doi.org/10.3892/or.2014.3130
MLA
Yin, J., Yuan, L., Liu, Z., Zhang, F., He, X., Xu, Z., Wang, Q., Du, X., Wu, X., Lu, J."Recombinant fusion proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M inhibit the proliferation of breast cancer cells in vitro". Oncology Reports 31.6 (2014): 2669-2675.
Chicago
Yin, J., Yuan, L., Liu, Z., Zhang, F., He, X., Xu, Z., Wang, Q., Du, X., Wu, X., Lu, J."Recombinant fusion proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M inhibit the proliferation of breast cancer cells in vitro". Oncology Reports 31, no. 6 (2014): 2669-2675. https://doi.org/10.3892/or.2014.3130